Holen Sie sich die Stockscreener-App
1.40
2.94%
0.04
Schlusskurs vom Vortag:
$1.36
Offen:
$1.35
24-Stunden-Volumen:
764.35K
Relative Volume:
1.35
Marktkapitalisierung:
$156.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-24.22M
KGV:
-5.0018
EPS:
-0.2799
Netto-Cashflow:
$-17.13M
1W Leistung:
+0.00%
1M Leistung:
+37.25%
6M Leistung:
+34.62%
1J Leistung:
+35.92%
1-Tages-Spanne:
$1.35
$1.46
1-Wochen-Bereich:
$1.29
$1.46
52-Wochen-Spanne:
$0.88
$1.59
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.40 | 154.12M | 0 | -24.22M | -17.13M | -0.2799 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-06-26 | Eingeleitet | ROTH MKM | Buy |
| 2024-04-22 | Eingeleitet | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Aktie (CRDL) Neueste Nachrichten
Cardiol Therapeutics CEO to discuss drug trials in interview By Investing.com - Investing.com Canada
Cardiol Therapeutics Showcases MAVERIC Phase III Trial and ARCHER Results in Barchart Live Interview - TipRanks
Cardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics (CRDL) CEO to discuss MAVERIC, ARCHER and CRD-38 in X interview - Stock Titan
Cardiol CEO goes live on X to discuss Phase III heart drug trial - Stock Titan
Cardiol Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
$30 Billion Per Year US Heart Failure Market Presents Huge Opportunity for Promising Drugs Advancing with Positive Trial Results for Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) - Barchart.com
Top Athira Pharma (LONA) Competitors 2026 - MarketBeat
Earnings Report: Is Cardiol Therapeutics Inc a cyclical or defensive stock2026 Pullback Review & High Yield Equity Trading Tips - baoquankhu1.vn
Cardiol Therapeutics Sets June 24, 2026 Date for Annual General Meeting of Shareholders - The Globe and Mail
3 Biotech Stocks Surge with Momentum - National Today
Cardiol Therapeutics (CRDL) sets June 24, 2026 AGM and May 7 record date - Stock Titan
Risk Off: Should I trade or invest in Cardiol Therapeutics Inc2026 Biggest Moves & Precise Trade Entry Recommendations - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL) - The Globe and Mail
CRDL Stock Price, Quote & Chart | CARDIOL THERAPEUTICS INC-A (NASDAQ:CRDL) - ChartMill
CRDL Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cardiol Therapeutics (CRDL) Receives 'Buy' Rating from Canaccord Genuity | CRDL Stock News - GuruFocus
Cardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from Canaccord Genuity Group - MarketBeat
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Hold at Wall Street Zen - MarketBeat
CRDL SEC FilingsCardiol Therapeu 10-K, 10-Q, 8-K Forms - Stock Titan
What is HC Wainwright's Estimate for CRDL FY2028 Earnings? - MarketBeat
CARDIOL THERAPEUTICS INC (CRDL.NE) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Cardiol Therapeutics Inc. (CA14161Y2006.SG) insider ownership and holdings - Yahoo Finance UK
Cardiol surpasses 50% enrollment in phase III pericarditis trial By Investing.com - Investing.com South Africa
Merger Talk: Will Cardiol Therapeutics Inc outperform the market in YEAR2026 Analyst Calls & High Accuracy Investment Signals - baoquankhu1.vn
Cardiol Therapeutics (NASDAQ:CRDL) Posts Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Cardiol Therapeutics Details 2025 Progress and Funding for Late-Stage Cardiac Drug Programs - TipRanks
Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis - marketscreener.com
Cardiol Therapeutics Initiated Pivotal Phase Iii Maveric Trial Of Cardiolrx In Recurrent Pericarditis - TradingView
Cardiol surpasses 50% enrollment in phase III pericarditis trial - Investing.com
Cardiol Therapeutics (NASDAQ: CRDL) advances 2025 cardiac trials and funding - Stock Titan
Heart drug trial passes halfway mark as Cardiol funds work into 2027 - Stock Titan
Cardiol Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cardiol Therapeutics Achieves MAVERIC Enrollment Milestone Amidst Approaching Cash Runway Deadline - Bitget
Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Cardiol Therapeutics (CRDL) files Form 40-F: 100.26M shares, audited 2025 results - Stock Titan
Cardiol Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView — Track All Markets
Fed Meeting: Can Cardiol Therapeutics Inc maintain its current growth rateWeekly Profit Recap & Technical Buy Zone Confirmation - baoquankhu1.vn
Cardiol Therapeutics (TSE:CRDL) Trading Up 10.5%Time to Buy? - MarketBeat
Earnings Recap: Can Cardiol Therapeutics Inc maintain its current growth rate2026 Analyst Calls & Community Consensus Trade Alerts - baoquankhu1.vn
Total debt of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Free cash flow of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Operating income of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Taxes of Cardiol Therapeutics Inc. Class A – HAM:CT9 - TradingView
Cardiol Therapeutics (CRDL) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Cardiol Therapeutics (TSX:CRDL) Expands Research Scope In Tsx Small Cap Index - Kalkine Media
If You Invested $1,000 in Cardiol Therapeu (CRDL) - Stock Titan
Cardiol Therapeutics (TSE:CRDL) Shares Down 1.5%Time to Sell? - MarketBeat
Cizzle Brands Corporation Releases Fiscal Q2 2026 Results - Investing News Network
HC Wainwright & Co. Reiterates Cardiol Therapeutics (CRDL) Buy Recommendation - MSN
Finanzdaten der Cardiol Therapeutics Inc-Aktie (CRDL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):